Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Erica K. Barnell et al.|Clinical Cancer Research|2020Cited by 368
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guièze, Catherine J. Wu, Vivian M. Liu et al.|Cancer Cell|2019Cited by 361
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Panagiotis A. Konstantinopoulos, D. Gulhan et al.|Nature Communications|2020Cited by 342
FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissuesAlba Font‐Tello, Henry W. Long, Nikolas Kesten et al.|Nature Protocols|2020Cited by 36